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Abstract: Gastric cancer is a global health problem accounting for 800,000 cancer related 
deaths annually. Often diagnosed at an advanced stage, the treatment of gastric cancer with 
chemotherapy is directed towards palliating cancer related symptoms with only modest 
improvements in survival. In addition, no regimen has emerged as a globally accepted standard. 
New therapeutic options are desperately needed for the treatment of gastric cancer. Docetaxel 
given in combination has recently emerged as a new option for patients with advanced gastric 
cancer. This review focuses on the treatment of advanced gastric cancer utilizing docetaxel-
based therapy and the novel additions of biotherapy to the existing cytotoxic platforms. In 
addition, the current investigations of docetaxel for the treatment of potentially curable gastric 
cancer will be discussed.
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Introduction
Although the rate of gastric cancer in developing countries has declined over the last 
50 years, gastric cancer remains the fourth most common cancer worldwide. For the 
year 2007, gastric cancer was estimated to be the second leading cause of cancer related 
death among men and the fourth among women, accounting for 800,000 cancer-related 
deaths overall (Garcia et al 2007) Gastric cancer is often diagnosed at an advanced 
stage when a cure is not possible, and treatment is palliative with the intent of improv-
ing the quality and quantity of life.
Early studies in advanced gastric cancer demonstrated a survival beneﬁ  t for 
patients treated with systemic chemotherapy compared with patients that received 
best supportive care alone (Murad et al 1993; Glimelius et al 1994; Pyrhonen et al 
1995). The backbone of early chemotherapy regimens was often 5-ﬂ  uorouracil 
(5-FU) or cisplatin (CDDP). After these early studies, several phase III trials were 
completed to determine the optimum chemotherapy regimen for the treatment 
of advanced gastric cancer. Commonly investigated regimens included FAMTX 
(5-FU, doxorubicin, high-dose methotrexate), FAM (5-FU, adriamycin, mitomy-
cin-C), ECF (epirubicin, CDDP, 5-FU), ELF (etoposide, leucovorin, 5-FU), and 
CF (CDDP, 5-FU). However, no globally accepted regimen emerged. In addition, 
the results were generally disappointing as response rates did not exceed 45% and 
the median survival time did not exceed 10 months in any study (Wils et al 1991; 
Webb et al 1997; Vanhoefer et al 2000; Ross et al 2002; Ohtsu et al 2003). Recently, 
docetaxel given in combination with cisplatin and 5-ﬂ  uorouracil has emerged as a 
new therapeutic option for patients with advanced gastric cancer. This review will 
focus on the beneﬁ  t of docetaxel for the treatment of gastric cancer, as well as the 
promising future directions.
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Docetaxel monotherapy
Initial investigations of single agent docetaxel revealed 
promising activity and suggested further evaluation was war-
ranted. Administration of docetaxel was commonly repeated 
every 3 weeks at a dose of 60–100 mg/m2. The overall response 
rate (ORR) in the front-line setting was 17%–24%, while in the 
salvage setting the ORR was 4.8%–22% (Sulkes et al 1994; 
Einzig et al 1996; Taguchi et al 1998; Graziano et al 2000; 
Mavroudis et al 2000; Bang et al 2002). The most common 
toxicities included neutropenia, leucopenia, nausea, vomiting, 
stomatitis, diarrhea, fatigue, and neuropathy. The early studies 
of docetaxel monotherapy indicated the taxane was well toler-
ated, active in advanced gastric cancer, and deserved further 
investigation in combination with other cytotoxic agents.
Docetaxel, cisplatin, and 5-FU
Based on the initial activity of docetaxel as a monotherapy, 
the V-325 study group developed docetaxel to be given in 
combination with CDDP and 5-FU (DCF). The initial phase of 
investigation compared the doublet of docetaxel (85 mg/m2) 
and CDDP (75 mg/m2) every 3 weeks (DC) with the triplet 
regimen of docetaxel (75 mg/m2), CDDP (75 mg/m2), and 
5-FU (750 mg/m2/day × 5 days) every 3 weeks in a random-
ized phase II trial (Ajani et al 2005). The purpose of this trial 
was for an independent data monitoring committee (IDMC) 
to select one of the two regimens to be the investigational 
arm in a future randomized phase III trial to be compared 
with the reference regimen of cisplatin and 5-FU. This trial 
enrolled and randomized 158 patients with advanced gastro-
esophageal cancer, of which 155 received treatment (DCF; 
n = 79, DC; n = 76). ORR rate favored DCF over DC; 43% 
and 26%, respectively. Time to progression (TTP) for DCF 
was 5.9 months vs 5.0 months for DC, while overall survival 
(OS) was 10.5 months for DC and 9.6 months for DCF. The 
DCF regimen was associated with more thrombocytopenia; 
otherwise hematologic toxicity was similar between the treat-
ment regimens. Non-hematologic toxicity was more common 
in the DCF arm and was mostly gastrointestinal in origin. 
Common toxicities included nausea, vomiting, stomatitis, 
diarrhea, and anorexia. Based on the higher conﬁ  rmed ORR 
for the DCF and acceptable toxicity proﬁ  le, DCF was chosen 
by the IDMC as the investigational regimen to be compared 
with CF in the planned phase III trial.
The second phase of development completed by the 
V325 study group was the multinational, multicenter, open 
label, phase III, randomized trial comparing DCF with the 
reference regimen CF (Van Cutsem et al 2006). The primary 
endpoint of the trial was to demonstrate the superiority of 
DCF compared with CF based on TTP. Secondary endpoints 
included OS, ORR, clinical beneﬁ  t, and quality of life. In less 
than 4 years, the V325 study group randomly assigned and 
treated 455 patients across 72 centers and 16 countries with 
DCF (n = 221) and CF (n = 224). The treatment arms were 
well balanced for baseline patient characteristics. Of note, 
97% of the patients overall had metastatic disease and 42% 
had more than 2 organ sites involved; representing a patient 
population with very advanced disease.
With a median follow up time of 13.6 months, the primary 
endpoint of the trial was achieved as DCF had a signiﬁ  cantly 
longer TTP compared with CF (5.6 months vs 3.7 months; 
p = 0.01). Overall survival was signiﬁ  cantly prolonged with 
DCF compared with CF (9.2 months vs 8.6 months; p = 0.02) 
and the ORR was higher with DCF (37%) compared with only 
25% with CF (p = 0.01). In addition, the percentage of patients 
treated with DCF and alive at 1 year was 40% vs only 32% 
for CF. At 2 years, the percent of patients alive was doubled 
with the DCF regimen as compared to CF (18% vs 9%).
As expected, the triplet regimen resulted in greater 
toxicity than the doublet regimen. DCF was associated 
with signiﬁ  cantly greater grade III/IV neutropenia (82% 
vs 57%), leucopenia (65% vs 31%), febrile neutropenia/ 
neutropenic infection (63% vs 27%), diarrhea (19% vs 8%) 
and neuropathy (17% vs 6%). It should be noted, that with 
the use of granulocyte colony stimulating factors (GCSF) 
as secondary prevention, the rate of complicated neutro-
penia was reduced to 12% with DCF as compared to 27% 
without GCSF in patients treated with DCF. In addition, 
infection (grade III or IV) was greater with DCF (20%) in 
patients greater than 65 years of age as compared to patients 
treated with CF (9%). The most common reason for treat-
ment discontinuation in both arms was progressive disease. 
However, disease progression as the reason for treatment 
discontinuation was less common with the DCF regimen 
(29.9% vs 43.8%). More patients treated with the DCF 
regimen withdrew consent (21.7 vs 11.6%) while similar 
numbers of patients discontinued treatment due to adverse 
events (treatment related or unrelated). Within 30 days of 
the last infusion of chemotherapy the number of deaths for 
DCF was 23 (10%) compared with 19 (8%) with CF. The 
toxicity associated with the DCF regimen underscores the 
need for proper patient selection to reduce the probability of 
signiﬁ  cant adverse events.
Although the acute treatment related toxicity was greater 
with the DCF regimen than the CF regimen, the increased 
toxicity did not appear to negatively affect quality of life 
or clinical beneﬁ  t. In fact, as part of the planned secondary Therapeutics and Clinical Risk Management 2008:4(5) 1001
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endpoint analysis, it was demonstrated that the DCF regimen 
signiﬁ  cantly prolonged the time to deﬁ  nitive detoriation in 
quality of life and time to deﬁ  nitive worsening of Karnofsky 
performance status (KPS) compared with CF (Ajani et al 
2007a, b). The time to weight loss and deﬁ  nitive worsening of 
appetite favored the DCF regimen but did not reach statistical 
signiﬁ  cance. There was no difference in pain-free survival or 
time to cancer-related opioid use between the two regimens. 
The superiority of the DCF regimen in quality of life and 
clinical beneﬁ  t is consistent with the previously mentioned 
improvements in TTP, OS, and ORR compared withj CF.
Modiﬁ  cations of the original DCF (mDCF) regimen 
have been pursued to evaluate the safety and efﬁ  cacy of 
the triplet regimen approach. In a large randomized phase 
II trial, Roth et al (2007) randomized patients to treatment 
with mDCF (docetaxel 85 mg/m2, cisplatin 75 mg/m2 and 
FU 300 mg/m2/d × 14 days), DC (docetaxel 85 mg/m2, 
cisplatin 75 mg/m2), or ECF (epirubicin 50 mg/m2, cisplatin 
60 mg/m2, and FU 200 mg/m2/day × 21 days). Each treat-
ment cycle was repeated every 3 weeks. 119 chemotherapy-
naïve patients with unresectable or metastatic gastric cancer 
were included in the analysis and were randomly assigned 
to treatment with mDCF, DC, or ECF. The independently 
reviewed ORR favored mDCF compared with ECF and 
DC (36.6%, 25%, and 18.4%, respectively). With a median 
follow-up time of 27.6 months, TTP favored mDCF and 
ECF (4.6 months vs 4.9 months respectively) compared 
with DC (3.6 months). OS was also improved with triplet 
therapy (mDCF = 10.4 months, ECF = 11.0 months) com-
pared with the doublet regimen (8.3 months). Toxicity was 
considerable for all three treatment regimens. Due to a high 
rate of febrile neutropenia in the docetaxel containing arms, 
a protocol amendment reduced the dose of docetaxel from 
85 to 75 mg/m2. The dose reduction resulted in a decrease in 
febrile neutropenia for mDCF and DC (mDCF 28%–12%, 
DC 15%–4%). Grade III or IV toxicities occurring in more 
than 10% of patients for the mDCF regimen included neu-
tropenia, febrile neutropenia, nausea/vomiting, alopecia, and 
diarrhea. Treatment delays greater than 7 days per cycle and 
per patient were most common with the ECF regimen com-
pared with mDCF and DC (ECF = 12%/5%, DCF = 6%/24%, 
DC = 3%/11%; per cycle and per patient, respectively). 
Unacceptable toxicity as a reason for treatment failure was 
more common with the ECF regimen, while patient refusal 
as a reason for treatment failure was more common with the 
mDCF regimen. However, it should be noted that 50% of 
the patients who refused further treatment with mDCF had 
received 6 or more cycles of therapy. Quality of life (QoL) 
scores were obtained at baseline and were well balanced 
between treatment arms. Functional QOL scores for emo-
tional functioning improved for all three regimens, while 
role functioning and numbness/paresthesia worsened for DC 
and mDCF, and remained the same for ECF. Constipation 
improved for mDCF at cycle 6 and remained the same for 
DC and ECF. Global health status improved with the ECF 
regimen, remained the same for mDCF, and declined for DC. 
Overall treatment burden was assessed by QoL forms and 
favored ECF compared with mDCF and DC after cycle 2 and 
cycle 6. The ﬁ  ndings of this study conﬁ  rm that the mDCF 
regimen is more promising than DC, although it is unclear if 
the modiﬁ  cations of the original DCF regimen signiﬁ  cantly 
improved the safety and tolerability.
Two other trials have been completed with modiﬁ  ed 
DCF regimens and have reported promising results. A trial 
by Lorenzen et al (2007) treated 60 patients with locally 
advanced (n = 24) or metastatic (n = 36) gastroesophageal 
adenocarcinoma with docetaxel (50 mg/m2) day 1, 15, 29, 
cisplatin (50 mg/m2) day 1, 15, 29, and 5-FU (2000 mg/m2) 
and leucovorin (400 mg/m2) weekly. Treatment was repeated 
every 8 weeks. The use of prophylactic GCSF support was not 
allowed in this trial. After treatment of the ﬁ  rst 15 patients, a 
protocol amendment reduced the dose of both docetaxel and 
cisplatin to 40 mg/m2 secondary to frequent grade III and 
IV toxicities. After modiﬁ  cation of the initial DCF regimen, 
treatment was generally well tolerated. As expected, hemato-
logic toxicity was common, but rates of grade III or IV neutro-
penia (22%), febrile neutropenia (5%) and thrombocytopenia 
(2%) were acceptable. Common non-hematologic toxicity 
with the mDCF regimen included grade III or IV diarrhea 
(20%), lethargy (18%), nausea (8%), and vomiting (8%). 
The mDCF regimen appeared to be an active regimen with 
an ORR of 47%, TTP of 9.4 months, and OS of 17.9 months. 
However, the survival data are misleading as 40% of the 
treated patients had locally advanced disease. Nevertheless, 
the regimen conﬁ  rms the activity of the triplet combination 
and the improved safety proﬁ  le is encouraging.
Another modiﬁ  cation of the DCF regimen was investi-
gated by Park et al (2005). They developed a mDCF regimen 
with low dose docetaxel (50 mg/m2) day 1 given in combina-
tion with cisplatin (80 mg/m2) day 1 and 5-FU (1200 mg/m2) 
day 1–3. The mDCF regimen was repeated every 3 weeks. 
(Park, Chun et al 2005) The ORR in 47 chemotherapy naïve 
patients with metastatic gastric cancer was 40%, while TTP 
was 4.6 months and OS was 9.7 months. Rates of grade III 
or IV neutropenia (68%) and febrile neutropenia/neutropenic 
infection (26%) were less common than previously reported Therapeutics and Clinical Risk Management 2008:4(5) 1002
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high dose DCF regimens. In addition, non-hematologic 
grade III or IV toxicities appeared slightly more favorable 
with the low dose docetaxel regimen (stomatitis 21%, diar-
rhea 4%, nausea/vomiting 0%) compared with the toxicity 
proﬁ  le of higher dose docetaxel regimens. However, the 
total dose of 5-FU in the mDCF regimen utilized by Park 
et al was 150 mg/m2 lower per cycle than traditional DCF 
(3750 mg/m2/cycle for DCF vs 3600 mg/m2/cycle for mDCF). 
5-FU was also infused over 3 days for mDCF compared 
with 5 days for DCF. The reduced total dose of 5-FU and 
decreased length of infusion may account for the decreased 
non-hematologic toxicity of the mDCF regimen. Regardless, 
the modiﬁ  ed DCF regimen conﬁ  rms the proof of principle 
that alterations of the original DCF regimen can achieve 
similar activity with more favorable toxicity proﬁ  les.
In summary, the pivotal trial performed by the V-325 
study group led to Food and Drug Administration approval 
for the use of docetaxel in combination with cisplatin and 
5-FU for the treatment of advanced gastric and gastroesopha-
geal adenocarcinoma. The addition of docetaxel to the che-
motherapy options for patients with advanced gastric cancer 
represents an important achievement. The toxicity associated 
with the DCF regimen is noteworthy and necessitates proper 
patient selection and subsequent aggressive management 
of toxicities. The use of GCSF for primary prophylaxis of 
neutropenia should be considered for all patients, as well as 
the use of a P/neurokinin 1 (NK1) receptor antagonist for 
chemotherapy-induced nausea and vomiting. In addition, 
modiﬁ  cations of the DCF regimen can result in similar 
activity and better tolerated treatment regimens (Table 1).
Docetaxel, oxaliplatin, and 5-FU
As noted previously, the toxicity proﬁ  le associated with the 
DCF regimen has led investigators to focus on modifying the 
DCF regimen so that treatment is better tolerated by patients. 
One promising approach is the substitution of oxaliplatin 
for cisplatin. It was demonstrated in the REAL-2 trial that 
oxaliplatin was not inferior to cisplatin when combined with 
epirubicin and 5-FU or capecitabine, based on the endpoints 
of OS and PFS (Cunningham et al 2008). Compared with 
cisplatin, oxaliplatin was associated with lower rates of 
neutropenia, alopecia, renal toxicity, and thromboembolism. 
However, oxaliplatin was associated with more diarrhea and 
neuropathy. Extrapolating from the REAL-2 trial results and 
incorporating the positive results from the V325 study, 2 trials 
have investigated treatment for advanced gastroesophageal 
cancer with docetaxel, oxaliplatin, and 5-FU.
Al-Batran et al enrolled 59 chemotherapy-naïve patients 
with advanced gastric cancer to be treated with docetaxel 
(50 mg/m2), oxaliplatin (85 mg/m2) leucovorin (200 mg/m2), 
and 5-FU via CIV (2.6 g/m2) over 24 hours (FLOT) (Al-Batran 
et al 2007). At the time of analysis (n = 57; 2 patients were 
found to have ineligible disease), ORR was 50.9% and disease 
stability rate was 70.2%. Survival data were available for 
52 patients and median PFS was 5.3 months while median OS 
was 11.3 months. The FLOT regimen appeared to have a more 
favorable safety proﬁ  le than the previously reported DCF 
regimen. Common grade III and IV toxicities with the FLOT 
regimen were neutropenia (46.3%), leukopenia (22.2%), 
neurosensory (9.3%), fatigue (9.3%), and diarrhea (14.8%). 
Febrile neutropenia was not common with the FLOT regimen 
(3.7%), and no treatment-related deaths were observed.
A phase I study initiated by Ajani et al (2007) was 
performed to determine the cycle 1, maximum tolerated dose 
of docetaxel when given in combination with oxaliplatin 
(85 mg/m2) and 5-FU via CIV (2.2 mg/m2) over 48 hours 
(D-FOX) every 2 weeks. Docetaxel was initiated at a dose 
of 20 mg/m2 in the typical 3 × 3 phase I clinical trial design. 
Table 1 Docetaxel in combination with cisplatin and 5-ﬂ  uorouracil
Study Treatment
(months)
Number of 
patients
Response 
rate (%)
Median PFS 
(months)
Median OS 
Van Cutsem DCF 224 37 5.6 9.2
(V-325) CF 221 25 3.7 8.6
Roth DCF
a 61 36.6 4.6 10.4
ECF 59 25 4.9 11.0
DC 58 18.4 3.6 8.3
Lorenzen DCF
b 60 47 9.4 17.9
Park DCF
c 47 40 4.6 9.7
aLow dose 5-FU with prolonged infusion.
bSplit dose DCF every 2 weeks.
cLow dose docetaxel.
Abbreviations: DCF, docetaxel, cisplatin, and 5-FU; ECF, epirubicin, CDDP, 5-FU; PFS, progression-free survival; OS, overall survival.Therapeutics and Clinical Risk Management 2008:4(5) 1003
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Subsequent dose escalations of docetaxel in were performed 
at intervals of 5 mg/m2. Preliminary results from the trial 
were presented in 2007. Response rate (43%), time to pro-
gression (6 months), and OS (13 months) suggested D-FOX 
was an active regimen in advanced gastric cancer (Tetzlaff 
et al 2008). The safety proﬁ  le of the D-FOX regimen was 
acceptable, as grade III/IV toxicities were not common. In 
addition, the trial did not utilize prophylactic GCSF support; 
yet febrile neutropenia and neutropenic infection were not 
common during any cycle and were absent during cycle 1. 
The phase I portion of the trial was recently completed and 
55 mg/m2 was selected as the dose of docetaxel to be given 
in combination with oxaliplatin and 5-FU in the phase II 
trial (Ajani unpublished data). The ﬁ  nal phase I results are 
awaited.
Several other studies have combined docetaxel with oxali-
platin (DO) ± capecitabine (DOX) in the ﬁ  rst-line setting for 
untreated metastatic gastroesophageal cancer (Grothe et al 
2006; Evans et al 2007; Kim et al 2008; Richards et al 2008). 
ORR for DO was 36%–45.2% and DOX was 19%–30%. OS 
reported for the two DO trials was 8.5 months to 9.9 months, 
respectively. The combination regimens were well tolerated 
with manageable toxicity (Table 2).
Docetaxel with irinotecan
Irinotecan is another active agent for the treatment of 
advanced gastroesophageal cancer. Irinotecan has a reported 
ORR of 14%–25% as a single agent, and 22%–51% when 
given in combination with 5-FU or cisplatin (Tetzlaff et al 
2008). Phase II trials have added docetaxel to be given with 
irinotecan; however, the results have been generally disap-
pointing. When docetaxel was given in combination with 
irinotecan, the response rate was 26%–45.7%, TTP/PFS was 
4.5 months and 4.2, respectively, and OS was 7.3–8.2 months. 
Since the addition of irinotecan in 2 recent phase III trials 
did not show a survival beneﬁ  t in the ﬁ  rst-line setting for 
advanced gastric cancer, it may not be ideal in the front-line 
setting and may account for the disappointing results when 
it has been given in combination with docetaxel (Dank et al 
2005; Boku et al 2007).
Docetaxel in combination 
with biotherapy
Bevacizumab
To develop the treatment of advanced gastric cancer beyond 
traditional cytotoxic therapy, research has focused on the 
development of biotherapy to be given in combination with 
chemotherapy. The development of biochemotherapy for 
advanced gastric cancer has focused on inhibition of vascular 
endothelial growth factor (VEGF), epidermal growth factor 
receptor (EGFR), and other pathways. Several biologic 
agents are under current investigation with the most mature 
results available for the monoclonal antibodies bevacizumab 
and cetuximab.
In a predominantly previously treated patient population, 
Enzinger et al evaluated single agent docetaxel (35 mg/m2 
day 1, 8, and 15) and bevacizumab (5 mg/kg day 1 and 15) in 
advanced gastroesophageal cancer, with the treatment cycle 
repeated every 4 weeks (Enzinger et al 2006). The ORR 
among 15 evaluable patients was 27%, with an additional 
38% of patient with stable disease as their best response. 
All four patients with a radiographic response to therapy 
had received prior chemotherapy for metastatic disease. 
Common grade III/IV toxicities for all 20 enrolled patients 
were fatigue (15%), gastrointestinal bleeding (15%), anemia 
(15%), neutropenia (10%), and arterial thrombosis (10%).
A modiﬁ  ed DCF regimen was developed by the gastro-
esophageal cancer group at the Memorial Sloan-Kettering 
Cancer Center to minimize the toxicity associated with the 
standard DCF regimen, and to be used as a platform for the 
addition of bevacizumab (Jhawer et al 2008). Treatment 
consisted of docetaxel (40 mg/m2), 5-FU bolus (400 mg/m2), 
leucovorin (400 mg/m2), and infusional 5-FU (1000 mg/m2 × 
2 days) with bevacizumab (10 mg/kg) day 1. On day 3, cispla-
Table 2 Docetaxel in combination with oxaliplatin ± 5-ﬂ  uorouracil or capecitabine
Study Treatment
(months) 
Number of 
patients
Response 
rate (%)
Median PFS 
(months)
Median OS 
Al-Batran FLOT 59 50.9 5.3 11.3
Ajani D-FOX 36 46 6.0 13.0
Kim DOX 42 45.2 5.7 9.9
Grothe DOX 14 30 3.9+ NR
+Censored.
Abbreviations: D, docetaxel; O, oxaliplatin; F, 5-ﬂ  uorouracil; X, capecitabine; L, leucovorin; PFS, progression-free survival; OS, overall survival; NR, not reported.Therapeutics and Clinical Risk Management 2008:4(5) 1004
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tin was given at a dose of 40 mg/m2. A preliminary analysis 
after enrolling 21 patients indicated an ORR of  71%, with 
81% of the patients progression free at 6 months. Grade III 
toxicities included neutropenia (50%), febrile neutropenia 
(15%), venous thromboembolism (29%), and fatigue (15%). 
Grade III hypertension, proteinuria, and perforation were not 
observed. The study continues to enroll patients with a target 
accrual of 44 patients.
A second trial reported by Enzinger (2008) utilized a 
more aggressive cytotoxic chemotherapy regimen with 
docetaxel as the backbone of therapy. Thirty-two patients 
were enrolled to be treated on day 1 and 8 with docetaxel 
(30 mg/m2), cisplatin (25 mg/m2), and irinotecan (50 mg/m2). 
Bevacizumab was given on day 1 of every 3-week cycle at a 
dose of 10 mg/kg. The biochemotherapy regimen appeared to 
have considerable activity in the chemotherapy-naïve patient 
population, with a partial response rate of 63% (an additional 
30% had stable disease as their best response). Toxicity of 
the regimen was consistent with prior experience, and gener-
ally well tolerated. In addition, UGT1A1 gene testing was 
predictive of severe diarrhea and neutropenia in patients with 
the *28 allele present.
As discussed above, the combination of docetaxel and 
oxaliplatin is considered to be a reasonable foundation for 
the addition of biotherapy. In a phase II trial reported by 
El-Rayes (2008), untreated patients with advanced gastric 
cancer were treated with docetaxel (70 mg/m2), oxali-
platin (75 mg/m2), and bevacizumab (7.5 mg/kg) every 3 
weeks. With only 8 evaluable patients enrolled on the trial 
to date, the ORR was 50% with an additional 50% with 
stable disease. Gastrointestinal perforation occurred in 2 
patients after cycle 2. Both patients had their primary tumor 
in place; one patient underwent surgical exploration and 
the other patient was medically managed. Other toxicities 
with the regimen include grade III IV neutropenia (38%), 
fever (13%), neuropathy (13%), and hypertension (13%). 
The biochemotherapy regimen appeared to be active in 
advanced gastric cancer. However the safety of bevaci-
zumab (eg, gastrointestinal perforation) was of concern.
Cetuximab
Several trials were recently reported on the clinical activity 
of cetuximab in combination with docetaxel. A monoclonal 
antibody, cetuximab is targeted to inhibit the EGFR pathway. 
Cetuximab is typically administered with an initial loading 
dose (400 mg/m2) followed by weekly maintenance therapy 
(250 mg/m2). As second-line therapy, Tebbut (2008) 
combined docetaxel (30 mg/m2) day 1 and 8 of a 3-week 
cycle with the traditional dosing schedule of cetuximab. 
Thirty-eight patients were accrued for therapy, and ORR was 
a modest 6%. With a median follow-up time of 19 months, 
PFS was 2.1 months and OS was 5.3 months. A subset 
analysis correlated increased grade of acneiform rash with 
improved PFS and OS, results that are consistent with prior 
studies of EGFR inhibitors. Grade III/IV toxicities with this 
salvage regimen included anorexia (16%), diarrhea (11%), 
nausea (8%), and acneiform rash (5%). Febrile neutropenia 
was uncommon (3%). There were no treatment related deaths 
with this regimen, but the 60-day all cause mortality was 
15.8%; potentially representing the poor prognosis of patient 
with treatment refractory gastric cancer.
In the front-line setting, Pinto (2008) treated 48 patients 
with the doublet regimen of docetaxel (75 mg/m2) plus 
cisplatin (75 mg/m2) every 3 weeks and standard dose cetux-
imab (DOCETUX). Patients were treated with the doublet 
regimen for a maximum of 6 cycles, but could continue 
with cetuximab in the absence of disease progression. In 
42 evaluable patients, ORR rate was 40.5% (1 complete 
response), and an additional 38.1% had stable disease as 
their best response. With 75% of the patients still alive at the 
time of reporting, PFS at 3 months was 80%, and survival 
data have not yet been presented. Toxicity assessment of 48 
evaluable patients showed the most common grade III/IV to 
be the hematologic toxicities of neutropenia (45.8%), febrile 
neutropenia (22.9%), and anemia (6.25%). Other toxicities 
included fatigue (22.9%), hyponatremia (20%), hypokalemia 
(16%), skin reaction (31.3%), vomiting (8.3%), and stomatitis 
(6.3%). There were 3 deaths within 60 days from the initiation 
of therapy, but the relationship with therapy was not clear. In 
a companion study of  21 patients treated with the DOCETUX 
regimen, it was shown that a reduction in basal VEGF levels 
in plasma and serum correlated with the disease control rate 
(Di Fabio 2008). These ﬁ  ndings suggest that this biochemo-
therapy regimen can affect circulating VEGF levels, and an 
early reduction in serum and plasma VEGF may be used as 
an early surrogate marker for disease control.
Although the results from the biochemotherapy trials are 
not mature at this time, the response rates and predictors of 
toxicity and response are of signiﬁ  cant interest (Table 3). It 
will be of great importance to complete well-designed phase III 
trials to deﬁ  ne the clinical beneﬁ  t of biochemotherapy in 
advanced gastric cancer. In addition, correlative studies to 
predict response to therapy and expected toxicity will be of 
signiﬁ  cant beneﬁ  t to patients and clinical oncologists, so that 
treatment can be tailored to the individual patient to maximize 
response while minimizing toxicity risks from treatment.Therapeutics and Clinical Risk Management 2008:4(5) 1005
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Localized gastric cancer
Several treatment strategies have emerged for the treat-
ment of localized gastric cancer. Options for localized 
gastric cancer in the Western Hemisphere include primary 
surgical resection followed by adjuvant chemoradiation, 
or perioperative chemotherapy and surgical resection (ie, 
preoperative chemotherapy, followed by surgical resection, 
and then adjuvant chemotherapy) (Macdonald et al 2001; 
Cunningham et al 2006). In the East, surgery consisting of 
a gastrectomy and a D-2 lymph node dissection followed by 
adjuvant chemotherapy with S-1 has been shown to improve 
overall survival compared to surgery alone (Sakuramoto et al 
2007). Since the beneﬁ  t of docetaxel has been established in 
the advanced disease setting, it is reasonable that docetaxel 
be investigated in the localized disease setting.
Utilizing a neoadjuvant approach for localized gastric 
cancer, Vuidez et al (2008) reported preliminary results of 
a phase I dose escalation study of docetaxel, oxaliplatin, and 
capecitabine given concurrently with radiotherapy. Dose 
escalation of docetaxel at intervals of 5 mg/m2 (starting at 
15 mg/m2 weeks 1, 2, 4, 5) was given with ﬁ  xed doses of 
oxaliplatin (50 mg/m2 weeks 1, 2, 4, 5) and capecitabine 
(650 mg/m2 twice daily Monday through Friday). Radia-
tion was completed to a total dose of 45 Gy in 25 fractions. 
Twenty-three patients were enrolled on the trial and it was 
determined that 25 mg/m2 was the recommended dose of 
docetaxel in this combination for future phase II trials. An 
R0 resection was achieved in 90% of the patients, and 68.4% 
of the patients had a major response to therapy (Becker 
criteria). Based on the promising results in advanced gastric 
cancer with the DOX regimen, and the high R0 resection 
rate in this trial, further investigation of this combination 
is warranted.
The Italian Trial in Medical Oncology (TIMO) group 
completed a feasibility study with docetaxel as adjuvant 
therapy in gastric cancer. They investigated sequential 
adjuvant chemotherapy for radically resected gastric cancer 
(Di Bartolomeo et al 2006). Patients were randomly assigned 
to treatment with 4 cycles of FOLFIRI followed by 4 cycles 
of docetaxel and cisplatin (DC), or assigned to treatment with 
mitomycin C (MMC) monotherapy for 6 cycles. 166 patients 
were enrolled and treated on the study (FOLFIR/DC; n = 85, 
MMC n = 81). With the exception of pN2–pN3 being more 
prevalent in the DC arm, the two arms were well balanced 
for baseline characteristics. The quality of surgical resection 
appeared reasonable in the trial, with a median of 25 lymph 
nodes examined, and 85% of patients having 15 or more 
lymph nodes sampled. Treatment in the polychemotherapy 
arm was generally well tolerated with 76% of the patients 
completing the planned sequential therapy. In the mono-
therapy arm, only 39% of patients completed treatment with 
MMC necessitating a protocol amendment to reduce the dose 
Table 3 Docetaxel in Combination with Biotherapy
Study Treatment Number of 
patients
Response 
rate (%) 
PFS Median  OS 
(months)
Enzinger Docetaxel/ 15 27 NR NR
Bevacizumab
Tebbutt Docetaxel/ 38a 6 2.1 months 5.3
Cetuximab
Jhawer mDCF/ 21 71 81% at 6 months NR
Bevacizumab
El-Rayes Docetaxel 8 50 NR NR
Oxaliplatin
Bevacizumab
Pinto Docetaxel 48 40.5 80% at 3 months NR
Cisplatin
Cetuximab
Enzinger Docetaxel 32 63 NR NR
Cisplatin
Irinotecan
Bevacizumab
aPreviously treated patients.
Abbreviations: PFS, progression-free survival; OS, overall survival; NR, not reported; mDCF, modifed docetaxel, cisplatin, and 5-FU regimen.Therapeutics and Clinical Risk Management 2008:4(5) 1006
Tetzlaff et al
of MMC to 8 mg/m2 for 4, rather than 6 cycles of therapy. 
The amended MMC therapy was more tolerable as 83% of 
the patients completed 4 cycles of MMC, and 72% did not 
require additional dose reductions. After a median follow 
up of 29 months, 3-year estimates of disease-free survival 
and OS favored the FOLFIRI/DC arm compared with the 
MMC arm; 67.4% vs 50.2% (p = 0.0449) and 73.5% vs 
62.4% (p = 0.1634) respectively. Some investigators suggest 
a multicenter national trial comparing sequential therapy 
with a standard reference regimen is warranted to conﬁ  rm 
the efﬁ  cacy of the FOLFIRI/DC strategy. However, it would 
be more intriguing to investigate the more active docetaxel-
based therapy chemotherapy regimens in the preoperative 
setting either in combination with biotherapy or radiation 
therapy.
Conclusion
The addition of docetaxel to the treatment options available 
for patients with advanced gastric and gastroesophageal junc-
tion adenocarcinoma is a notable achievement. With careful 
patient selection and aggressive supportive measures, DCF 
represents a reasonable treatment option. Modiﬁ  cations to the 
dose and schedule of the DCF regimen can improve the safety 
and tolerance of docetaxel-based therapy for patients. In addi-
tion, the substitution of cisplatin with oxaliplatin to create 
the D-FOX regimen has demonstrated promising results for 
docetaxel-based therapy. Several phase III trials are ongoing 
and recruiting patients for treatment with gastroesophageal 
cancer (Table 4). In addition, phase II trials investigating the 
addition of biotherapy to docetaxel-based therapy are promis-
ing, and may signiﬁ  cantly advance the impact of systemic 
therapy. In addition, the incorporation of docetaxel in the neo-
adjuvant and adjuvant setting is under active investigation, 
and may improve the beneﬁ  ts of multimodality therapy for 
potentially curable gastric cancer.
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